Molecular Therapy Nucleic Acids is a premier open-access journal published by CELL PRESS, dedicated to advancing the field of molecular medicine through the innovative application of nucleic acid-based therapies. Since its inception in 2012, this journal has become an essential resource for researchers and professionals in drug discovery and molecular medicine, reflected in its status as a Q1 journal in both categories for 2023. With a notable impact factor and high rankings in Scopus, including #8 out of 157 in Drug Discovery and #16 out of 178 in Molecular Medicine, it serves to disseminate groundbreaking research and foster collaborations among scientists worldwide. The journal's comprehensive scope encompasses a wide variety of topics, including gene therapy, RNA interference, and CRISPR technology, ensuring that it remains at the forefront of scientific excellence. With open access availability, Molecular Therapy Nucleic Acids actively promotes the widespread dissemination of knowledge, making its crucial insights accessible to students, researchers, and industry professionals alike.

Molecular Cell, published by Cell Press, is a leading journal in the fields of cell biology and molecular biology. Established in 1997, this prestigious journal boasts a significant impact within the scientific community, evidenced by its impressive 2023 Scopus rankings, placing it in the top 2% of its field (Rank #10/410 in Molecular Biology, Rank #12/285 in Cell Biology). With a focus on cutting-edge research that bridges the gap between molecular genetics and cellular function, Molecular Cell serves as an essential platform for the dissemination of vital findings and innovative methodologies. Although it follows a traditional publishing model without Open Access options, its rigorous peer-review process and high standards ensure that articles published within these pages are of the utmost quality, making it an invaluable resource for researchers, professionals, and students alike seeking to stay at the forefront of scientific discovery. The journal's address is 50 Hampshire St, Floor 5, Cambridge, MA 02139, United States, reinforcing its commitment to fostering scientific excellence and collaboration.

Frontiers in Genome Editing, published by FRONTIERS MEDIA SA, stands at the forefront of genomic research, specializing in the rapidly evolving realm of gene editing technologies. With an enthusiastic commitment to open access since 2020, this journal facilitates unrestricted distribution of cutting-edge research, making significant advancements in biotechnology and genetics accessible to a global audience. Located in Lausanne, Switzerland, Frontiers in Genome Editing publishes high-quality, peer-reviewed articles that contribute to the understanding and application of genome editing tools, such as CRISPR and TALEN, in various biological fields. Notably, as of 2023, the journal holds a prestigious Q1 ranking in Biotechnology and a Q2 ranking in Genetics, underscoring its importance and influence within these disciplines. With robust Scopus rankings, including a notable percentile placement, Frontiers in Genome Editing is an invaluable resource for researchers, professionals, and students dedicated to the promising future of genomic innovation.

Nature Plants is a premier journal dedicated to the dynamic and interdisciplinary field of plant science, published by NATURE PORTFOLIO in the United Kingdom. With an impressive impact factor placing it in the top tier of scholarly journals—ranking Q1 in Plant Science for 2023—this journal sets a high standard for research dissemination. Nature Plants has maintained a remarkable Scopus Rank of 5 out of 516 in the Agricultural and Biological Sciences category, reflecting its pivotal role in advancing knowledge in the field. The journal aims to provide a platform for groundbreaking research that addresses key challenges in plant biology, ecology, and agriculture, thereby fostering a deeper understanding of plant science's contribution to global sustainability. Although primarily non-open access, it offers exclusive insights and robust discussions, making it an indispensable resource for researchers, professionals, and students eager to explore the latest advancements and innovations in plant science.

Cell Stem Cell, published by CELL PRESS, is a premier journal at the forefront of cellular biology, genetics, and molecular medicine. With an esteemed impact factor and recognized as a Q1 journal in multiple categories including Cell Biology, Genetics, and Molecular Medicine, it offers researchers, professionals, and students rigorous, peer-reviewed articles that shape the future of stem cell research and regenerative medicine. Located in Cambridge, MA, this journal has become an invaluable resource since its inception in 2007 and is committed to disseminating groundbreaking findings that drive innovation and understanding in these critical fields. By consistently ranking within the top percentile of its categories in Scopus, Cell Stem Cell remains an essential platform for scholarly communication, fostering collaboration among leading scientists worldwide. Although the journal does not currently offer open access options, its comprehensive insights are pivotal for anyone engaged in the study of stem cells and their applications.

BIOTECHNOLOGY & BIOTECHNOLOGICAL EQUIPMENT is a leading open access journal published by TAYLOR & FRANCIS LTD from the United Kingdom, dedicated to advancing the field of biotechnology since its inception in 1990. Committed to disseminating high-quality research, the journal has transitioned to open access since 2014, enhancing its accessibility for researchers, professionals, and students alike. With a notable impact in the field, it is categorized in the Q3 quartile for Biotechnology as of 2023 and ranks #193 out of 311 in the Scopus categories for Biochemistry, Genetics, and Molecular Biology. The journal aims to cover a diverse range of topics related to both biotechnological advancements and the equipment that supports them, thus fostering innovative research and practical applications in the biotechnology sector. With an evolving scope that reflects the dynamic nature of biological research, BIOTECHNOLOGY & BIOTECHNOLOGICAL EQUIPMENT plays a crucial role in bridging the gap between laboratory studies and real-world applications, making it an essential resource for anyone involved in biotechnology research.

Plant Biotechnology is a distinguished journal published by the Japanese Society for Plant Cell and Molecular Biology, committed to advancing the field of plant biotechnology through the dissemination of high-quality research. With an ISSN of 1342-4580, this journal caters to a global audience interested in agronomy, crop science, and plant molecular biology. The journal has achieved notable rankings, including Q2 in Agronomy and Crop Science and Q2 in Plant Science, underscoring its relevance and impact in these fields according to the latest 2023 metrics. Furthermore, it holds a respectable position within Scopus rankings across multiple categories, indicating its contribution to the academic community. Although it is not an open-access journal, its regular publications, spanning from 1997 to 2024, feature cutting-edge studies that explore innovative approaches and technologies in plant science. Researchers, professionals, and students will find Plant Biotechnology an essential resource for staying informed on significant advancements and trends in plant research.

aBIOTECH, published by SPRINGERNATURE, is a premier academic journal dedicated to advancing the fields of biotechnology, agronomy, and molecular biology. With an impressive ISSN of 2096-6326 and E-ISSN 2662-1738, this journal has established itself as a vital resource for researchers and professionals aiming to publish high-quality, impactful studies. Based in Singapore, aBIOTECH has achieved remarkable recognition, boasting a Q1 ranking in multiple categories including Agronomy and Crop Science, Biochemistry, and Genetics in the 2023 Scopus rankings. Its solid position in the 90th percentile for Biochemistry and Genetics reinforces its significance within the global scientific community. The journal covers a broad spectrum of topics relevant to both basic and applied research, facilitating a shared dialogue amongst scientists and encouraging collaborative progress in innovative biotechnological applications. The open-access nature of the journal ensures that cutting-edge research is freely available, fostering a global exchange of ideas that is critical to the advancement of science today.

Applied Biochemistry and Biotechnology is a leading journal published by Springer, dedicated to advancing research in the interdisciplinary fields of biochemistry, biotechnology, and applied microbiology. Established in 1981, this peer-reviewed journal covers a wide range of topics that encompass innovative techniques, methodologies, and applications of biochemistry and biotechnology in medicine, environmental engineering, and molecular biology. With a Q2 ranking in several categories and an increasing impact factor, the journal demonstrates significant influence and credibility within the scientific community. While traditionally subscription-based, the journal offers avenues for open access through selective agreements, making high-quality research accessible to a broader audience. Researchers, professionals, and students alike will find Applied Biochemistry and Biotechnology to be an invaluable resource for the latest developments and applications in biochemistry and its related fields, aiding in the quest for sustainable solutions and novel biotechnological advancements.

CURRENT GENE THERAPY is a leading journal in the field of gene therapy, offering a platform for researchers and professionals to publish their findings related to innovative approaches in gene-based treatments. Published by Bentham Science Publishers Ltd, this journal, with its ISSN 1566-5232 and E-ISSN 1875-5631, is indexed in respected databases, enhancing its visibility and impact in the scientific community. As of 2023, it holds a commendable impact factor, with categorized quartile rankings reflecting its influence, especially in Drug Discovery (Q2), Genetics (Q3), and Molecular Medicine (Q3). Although it follows a subscription model, the journal aims to bridge the gap between laboratory research and clinical applications, attracting submissions that provide critical insights into gene therapy advancements from 2001 to 2024. The editorial scope covers various aspects of gene therapy, including experimental studies and clinical trials, underlining its commitment to fostering knowledge that addresses genetic disorders and enhances therapeutic efficacy. Whether you are a researcher, clinician, or student, CURRENT GENE THERAPY serves as an invaluable resource at the forefront of genetic research and medical innovation.